

06th October, 2026

To, The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025	To, The Secretary, National Stock Exchange (NSE), Exchange Plaza, 5 th Floor Plot No.C/1, 'G' Block Bandra - Kurla Complex Mumbai - 400 051. Symbol - KIMS
--	--

Dear Sir/ Madam

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition of Equity Stake in Splendid Hospitals Private Limited (Kompally), an O & M entity by investing upto Rs. 40.00 Cr, by way of primary infusion – Reg.

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of Krishna Institute of Medical Sciences Limited (“**the Company**”) at its meeting held on today, i.e. 06th October, 2026 has approved the proposal for acquisition of equity stake of Splendid Hospitals Private Limited (Kompally), an O & M entity by investing upto Rs. 40.00 Cr, by way of primary infusion.

We enclose herewith the details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as an **Annexure-I** to this letter.

Kindly take the above intimation on your records. This intimation is also uploaded on the Company’s website at: <https://www.kimshospitals.com/investors/> > **Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015 > Intimations filed by the Company > Intimations under Regulation 30.**

Thanking You,

Yours truly

For Krishna Institute of Medical Sciences Limited

NAGAJAYANTHI
JUTTUR
RAGHAVENDRA
DAS
Digitally signed by
NAGAJAYANTHI JUTTUR
RAGHAVENDRA DAS
Date: 2026.10.06
19:45:13 +05'30'

Nagajayanthi J.R
Company Secretary and Compliance Officer

ANNEXURE -1

a	Name of the target entity, details in brief such as size, turnover, etc.,	Name of the target entity: Splendid Hospitals Private Limited (Kompally). <u>Details in brief:</u> SPLENDID HOSPITALS PRIVATE LIMITED ('Splendid'), is a company incorporated and existing under the Companies Act, 2013 and having its registered office at Plot no 339/340 road no.4 Remedy Hospitals KPHB Colony Kukatpally, Hyderabad, Telangana, 500072. The hospital has the potential due to the location and demand for hospital services and has the capacity to expand to over 225+ beds and is equipped with the latest medical infrastructure, medical and diagnostic equipment, and multiple operation theatres. (Rs. in Crore) <table><tr><th colspan="2">FY 2025-26</th></tr><tr><td>Turnover:</td><td>1.39</td></tr><tr><td>PAT:</td><td>-8.92</td></tr><tr><td>Networth:</td><td>38.69</td></tr></table>	FY 2025-26		Turnover:	1.39	PAT:	-8.92	Networth:	38.69
FY 2025-26										
Turnover:	1.39									
PAT:	-8.92									
Networth:	38.69									
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "Arms length":	Acquisition of equity shares does not fall within the definition of Related Party Transaction.								
c	Industry to which the entity being acquired belongs:	Healthcare Industry								
d	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	KIMS being the O & M Partner of the target entity has decided to acquire the equity stake as a strategic investment.								
e	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable.								
f	Indicative time period for completion of the acquisition	On or before 31.03.2027.								
g	Consideration - whether cash consideration or share swap and details of the same:	Cash.								

h	Cost of acquisition or the price at which the shares are acquired;	The shares will be acquired based on the valuation report issued by BDO Valuation Advisory LLP, dated 05 th October, 2026, for an aggregate consideration of up to ₹40.00 Crore (Rupees Fourty Crore only).								
i	Percentage of shareholding/control acquired and/or number of shares acquired;	KIMS will acquire upto 22% of equity shares of Rs. 10 each, for an aggregate consideration of upto ₹40.00 Crore (Rupees Fourty Crore only), by way of primary infusion.								
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence, and any other significant information (in brief):	Brief background about the entity acquired: As mentioned in serial no. (a) Date of Incorporation: 20-09-2022 History of last 3 years Total Turnover of the Company: <table border="1"><thead><tr><th>Particulars</th><th>Amount in Crores</th></tr></thead><tbody><tr><td>FY26</td><td>1.39</td></tr><tr><td>FY25</td><td>0.30</td></tr><tr><td>FY24</td><td>0.00</td></tr></tbody></table> Presence: Kompally, Telangana - India Other Significant Information: please refer to the aforementioned.	Particulars	Amount in Crores	FY26	1.39	FY25	0.30	FY24	0.00
Particulars	Amount in Crores									
FY26	1.39									
FY25	0.30									
FY24	0.00									